Human circulating CD24hi marginal zone B cells produce IgM targeting atherogenic antigens and confer protection from vascular disease

Nat Cardiovasc Res. 2023 Nov;2(11):1003-1014. doi: 10.1038/s44161-023-00356-1. Epub 2023 Oct 30.

Abstract

IgMs that inactivate oxidation-specific epitopes (IgMOSE), which are secondary products of lipid peroxidization, protect against inflammatory diseases, including diet-induced atherosclerosis. However, the human B cell subtype that produces IgMOSE remains unknown. In this study, we used single-cell mass cytometry and adoptive transfer of B cell subtypes to NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice to identify B27+IgM+CD24hi cells as the major producers of IgMOSE in humans. Notably, these cells have characteristics of human circulatory marginal zone B (MZB) cells, which are known to be atheoroprotective IgM producers in mice. CD24 antibody treatment to reduce MZB cells and IgM in a hyperlipidemic humanized mouse model provides the evidence that MZB cells protect against vascular inflammation. Consistent with these findings, the frequency of B27+IgM+CD24hi cells (MZB) in patients inversely correlates with coronary artery disease severity.

MeSH terms

  • Adoptive Transfer
  • Aged
  • Animals
  • Atherosclerosis* / immunology
  • B-Lymphocyte Subsets / immunology
  • B-Lymphocyte Subsets / metabolism
  • B-Lymphocytes / immunology
  • CD24 Antigen* / immunology
  • CD24 Antigen* / metabolism
  • Coronary Artery Disease / blood
  • Coronary Artery Disease / immunology
  • Disease Models, Animal
  • Female
  • Humans
  • Immunoglobulin M* / immunology
  • Male
  • Mice
  • Mice, Inbred NOD*
  • Middle Aged

Substances

  • Immunoglobulin M
  • CD24 Antigen